Cotización Phaxiam Therapeutics - 0QSS

	Precios en Tiempo Real	Nivel 2
Forex

Herramientas de nivel profesional para inversores individuales.

Premium

Último Precio

71.025

Postura de Compra

6.925

Postura de Venta

7.28

Volume Operado de la Acción

0.00

0.00 Rango del Día 0.00

71.025 Rango de 52 semanas 71.025

Capitalización de Mercado [m]

431.477M

Precio Anterior

71.025

Precio de Apertura

Hora

(O)

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

6,075,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.40

Beneficio por acción (BPA)

-3.87

turnover

1.33M

Beneficio neto

-23.49M

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.phaxiam.com

Sede

Lyon, Rhone, Fra

Fundado

Phaxiam Therapeutics is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QSS. The last closing price for Phaxiam Therapeutics was 71.03 €. Over the last year, Phaxiam Therapeutics shares have traded in a share price range of 71.025 € to 71.025 €.

Phaxiam Therapeutics currently has 6,075,000 shares in issue. The market capitalisation of Phaxiam Therapeutics is 431.48 € million. Phaxiam Therapeutics has a price to earnings ratio (PE ratio) of -0.40.

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »

PHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day » PHAXIAM a présenté son test IVD Phagogramme et l’actualisation...

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility...

PHAXIAM publie l’information financière du troisième trimestre 2024

PHAXIAM publie l’information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie de 5,7 M€ au 30 septembre 2024Exécution de la stratégie clinique conforme au plan, avec...

PHAXIAM Reports Third-Quarter 2024 Financial Information

PHAXIAM Reports Third-Quarter 2024 Financial Information Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase...

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Monthly information related to total number of voting rights and shares...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Information mensuelle relative au nombre total de droits de vote et...

PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis

PHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-Unis GLORIA, 1ère étude mondiale de phagothérapie de phase II dans le traitement...

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024 Place de cotation : Euronext Paris (Compartiment C - Code ISIN :...

Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024

Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024 Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1...

Período †	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	71.025	71.025	71.025	0	0	DE
4	71.025	71.025	71.025	5	71.025	DE
12	71.025	71.025	71.025	2	71.025	DE
26	71.025	71.025	71.025	3	71.025	DE
52	71.025	71.025	71.025	2	71.025	DE
156	71.025	71.025	71.025	1516	71.025	DE
260	71.025	71.025	71.025	1951	71.025	DE

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
ORCPOracle Power Plc	0.0305p (158.47%)	6.24B
STKStreaksai Plc	0.35p (59.09%)	8.58M
QEDQuadrise Plc	3.62p (57.39%)	94.06M
ENWEnwell Energy Plc	23.00p (46.03%)	160.81k
WEBWebis Holdings Plc	0.125p (38.89%)	9.14M
INXI-nexus Global Plc	1.50p (-52.38%)	7.25M
SFRSeverfield Plc	55.60p (-36.24%)	9.71M
LENDSancus Lending Group Limited	0.30p (-33.33%)	1.23M
TRYBTribe Technology Plc	2.45p (-20.97%)	80k
GWMOGreat Western Mining Corporation Plc	0.0175p (-20.45%)	169.92M
ORCPOracle Power Plc	0.0305p (158.47%)	6.24B
NTVONativo Resources Plc	0.0025p (0.00%)	3.46B
TRPTower Resources Plc	0.0275p (0.00%)	526.88M
CPXCap-xx Limited	0.145p (-13.43%)	499.92M
MSMNMosman Oil And Gas Limited	0.038p (-1.30%)	329.43M